From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France
Months
N
%
≤ 3
85
27.8
]3-6]
84
27.4
>6
127
41.5
Ongoing treatment
10
3.3
